Lessons from similarities between SLE and HIV infection

Journal of Infection

Volumn 44, Issue 2, 2002, Pages 67-72

  Sekigawa, I ^a   Okada, M ^b   Ogasawara, H ^b   Naito, T ^b   Kaneko, H ^b   Hishikawa, T ^b   Iida, N ^a   Hashimoto, H ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE; CYTOKINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOSUPPRESSIVE AGENT; NEUTRALIZING ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; STEROID; VIRUS ANTIBODY; VIRUS ANTIGEN;

B LYMPHOCYTE ACTIVATION; CLINICAL FEATURE; CLONAL ANERGY; COMPARATIVE STUDY; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; LYMPHOCYTOPENIA; MOLECULAR MIMICRY; OPPORTUNISTIC INFECTION; PATHOGENESIS; POLYCLONAL ACTIVATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXOPLASMOSIS; VIRUS DETECTION;

EID: 0036068174     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2001.0959     Document Type: Article

References (57)

1. Retroviruses and systemic lupus erythematosus
2. The potential roles of endogenous retroviruses in autoimmunity
3. Systemic lupus erythematosus - Is a viral aetiology a credible hypothesis?
4. Retroviruses and autoimmunity
5. Detection of antibodies to recombinant gag protein derived from human endogenous retrovirus like sequence, clone 4-1, in autoimmune diseases
6. Molecular mimicry between human endogenous retrovirus clone 4-1 and HLA class I antigen: With reference to the pathogenesis of systemic lupus erythematosus
7. Sequence analysis of human endogenous retrovirus clone 4-1 in systemic lupus erythematosus
8. Quantitative analyses of messenger RNA of human endogenous retrovirus in SLE patients
9. Quantitative comparison of human endogenous retrovirus mRNA between SLE and rheumatoid arthritis
10. Endogenous retroviruses in pathogenesis of autoimmunity
11. HIV infection and SLE: Their pathogenic relationship
12. False-positive human immunodeficiency virus testing in patients with lupus erythematosus
13. Human immunodeficiency virus infection in systemic lupus erythematosus
14. Renal manifestations of concurrent systemic lupus erythematosus and HIV infection
15. Effects of IV cyclophosphamide on HIV viral replication in a patient with systemic lupus erythematosus
16. Emergence of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for human immunodeficiency virus infection
17. + T cell ratio and T cell activation in systemic lupus erythematosus
18. + T cells and their derived cytokine, IL-16, in SLE
19. Lymphocyte phenotyping in infants: Maturation of lymphocyte subpopulations and the effects of HIV infection
20. Changing virus-host interactions in the course of HIV-1 infection
21. + T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus
22. T lymphocyte, natural killer cells, cytokines, and immune regulation
23. Role of TH1/TH2 cytokines in HIV infection
24. In vitro type-1 and type-2 cytokines production in systemic lupus erythematosus: Lack of relationship with clinical disease activity
25. Change in circulating level of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient indinavir
26. Circulating levels of β-chemokines in systemic lupus erythematosus
27. Role of tumor necrosis factor (TNF)-α in the induction of HIV-1 gp120-mediated CD4+ T cell anergy
28. Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p561ck in human CD4 lymphocytes
29. Inhibition of CD4+ T cell function by the HIV envelope protein gp120
30. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120
31. Gp120 ligation of CD4 induces p561ck activation and TCR desensitization independent of TCR tyrosine phosphorylation
32. Membratumor necrosis factor-α is involved in the polyclonal B-cell activation induced by HIV-infected human T cells
33. The production of β-chemokine induced by HIV envelope glycoprotein
34. Differences of HIV envelope protein between HIV-1 and HIV-2: Possible relationship to the lower virulence of HIV-2
35. HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumor necrosis factor-α
36. Breakdown of self-tolerance and the pathogenesis of autoimmunity
37. Interleukin 16 and its function as a CD4 ligand
38. Interleukin-16
39. Circulating IL-16 in systemic lupus erythematosus
40. Treatment of solid tumors should obligatorily be combined with the in vivo codepletion of tumor-protecting, CD8+/HLA-DR(+)-suppressor T cells by alloreactive donor T cells whose preprogrammed cell death allows a before GvHD can be established. Results of animal experiments, in more than 6000 mice
41. Naturally occurring antibody response to DNA is associated with the response to retroviral gp70 in autoimmune New Zealand mice
42. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene
43. Detection of antibodies to HIV-1 gp41 and HLA class II antigen-derived peptides in SLE patients
44. Syncytial cell formation in vivo by type C retroviral particles in the systemic lupus erythematosus (SLE)
45. Immunosuppressive retroviral peptides: Immunopathological implications for immunosuppressive influences of retroviral infections
46. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity by gp41 of human immunodeficiency virus type 1
47. Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation
48. Mechanisms of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo
49. Interaction of MHC class I molecules with the transporter associated with antigen processing
50. The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus
51. Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41
52. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease
53. Infection in systemic lupus erythematosus
54. Immune restoration disease in HIV-infected patients after antiretroviral therapy
55. Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: With emphasis on EB virus, human herpesvirus 6 and hepatitis C virus
56. HIV: Vaccines out of Africa
57. Expression of an endogenous retroviral gene product in human placenta